Immunomedics, Inc. Reports Multiple Objective Responses in Solid Cancers With IMMU-132
Published: Oct 23, 2013
BOSTON, Oct. 22, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that its newest antibody-drug conjugate (ADC), IMMU-132, has produced durable partial responses in three different cancer types in early phase of clinical evaluation.
Help employers find you! Check out all the jobs and post your resume.